Noxopharm (ASX:NOX) receives approval from U.S. FDA for Veyonda
- Clinical drug development company Noxopharm (NOX) has received approval from the U.S. Food and Drug Administration for its Veyonda cancer treatment
- This approval will see Noxopharm begin a study in using Veyonda to treat cancerous cells found in fat, blood and muscle tissue
- Chief Medical Officer Gisela Mautner said the drug met the FDA's very high standard as a safe and well-tolerated drug
Add to My Watchlist
What is My Watchlist?
